Established in 2009 and located in the San Francisco Bay Area, Novodiax is focused on the development of tissue-based diagnostics. It is currently transitioning from an R&D startup to a commercial company. Novodiax has successfully developed a proprietary "Direct IHC” technology, in which a primary antibody is labeled with a unique PolyHRP, forming a new molecule that still works well in tissue-based immunoassay. Novodiax has further identified two unique applications for this technology. Each targets a formerly unmet medical or diagnostic need.